Menu

Blog

Archive for the ‘biotech/medical’ category: Page 2003

Aug 8, 2019

Has this scientist finally found the fountain of youth?

Posted by in categories: biotech/medical, genetics, life extension

The black mouse on the screen sprawls on its belly, back hunched, blinking but otherwise motionless. Its organs are failing. It appears to be days away from death. It has progeria, a disease of accelerated aging, caused by a genetic mutation. It is only three months old.

I am in the laboratory of Juan Carlos Izpisúa Belmonte, a Spaniard who works at the Gene Expression Laboratory at San Diego’s Salk Institute for Biological Studies, and who next shows me something hard to believe. It’s the same mouse, lively and active, after being treated with an age-reversal mixture. “It completely rejuvenates,” Izpisúa Belmonte tells me with a mischievous grin. “If you look inside, obviously, all the organs, all the cells are younger.”

Izpisúa Belmonte, a shrewd and soft-spoken scientist, has access to an inconceivable power. These mice, it seems, have sipped from a fountain of youth. Izpisúa Belmonte can rejuvenate aging, dying animals. He can rewind time. But just as quickly as he blows my mind, he puts a damper on the excitement. So potent was the rejuvenating treatment used on the mice that they either died after three or four days from cell malfunction or developed tumors that killed them later. An overdose of youth, you could call it.

Aug 8, 2019

Bill Faloon: A Life Long Quest To Reverse Human Aging!

Posted by in categories: bioengineering, biotech/medical, cryonics, education, food, life extension, quantum physics, transhumanism

Ira Pastor, ideaXme longevity and aging Ambassador and Founder of Bioquark interviews Bill Faloon, Director and Co-Founder, Life Extension Foundation and Founder of The Church Of Perpetual Life.

Ira Pastor Comments:

Continue reading “Bill Faloon: A Life Long Quest To Reverse Human Aging!” »

Aug 8, 2019

Young blood cocktail stops Alzheimer’s decline, early clinical trial reports

Posted by in categories: biotech/medical, neuroscience

Alkahest, a California-based biotech start-up, has just revealed some compelling early results from an ongoing Phase 2 trial into the efficacy of its novel formulation of plasma proteins derived from young blood, developed to slow, or even stop, the cognitive decline associated with Alzheimer’s disease.

Aug 8, 2019

Thousands of “indestructible” tardigrades could be living on the moon after spaceship crash

Posted by in categories: biotech/medical, military, space travel

The tardigrades were part of a “lunar library” that Spivack’s foundation had put together. According to Wired, the package was about the size of a DVD and contained human DNA—including Spivack’s own—as well as 30 million pages of information on mankind’s knowledge and thousands of dehydrated tardigrades.

Tardigrades are known as one of the toughest creatures on Earth. They are microscopic, measuring about 0.012 to 0.020 inches in length, and can withstand temperatures of up to 304 degrees Fahrenheit and can survive being frozen alive. One tardigrade is known to have survived being frozen for 30 years. They can also live without water for up to a decade by shriveling up and placing themselves in a state of suspended animation—a trait DARPA is currently studying in the hope of preserving soldiers injured on the battlefield.

Aug 8, 2019

China’s CRISPR push in animals promises better meat, novel therapies, and pig organs for people

Posted by in categories: biotech/medical, food, genetics, life extension

In addition to having access to large colonies of monkeys and other species, animal researchers in China face less public scrutiny than counterparts in the United States and Europe. Ji, who says his primate facility follows international ethical standards for animal care and use, notes that the Chinese public has long supported monkey research to help human health. “Our religion or our culture is different from that of the Western world,” he says. Yet he also recognizes that opinions in China are evolving. Before long, he says, “We’ll have the same situation as the Western world, and people will start to argue about why we’re using a monkey to do an experiment because the monkey is too smart, like human beings.”


This story, one in a series, was supported by the Pulitzer Center.

BEIJING, GUANGZHOU, JIANGMEN, KUNMING, AND SHANGHAI—Early one February morning, researchers harvest six eggs from a female rhesus macaque—one of 4000 monkeys chirping and clucking in a massive outdoor complex of metal cages here at the Yunnan Key Laboratory of Primate Biomedical Research. On today’s agenda at the busy facility, outside Kunming in southwest China: making monkey embryos with a gene mutated so that when the animals are born 5 months later, they will age unusually fast. The researchers first move the eggs to a laboratory bathed in red light to protect the fragile cells. Using high-powered microscopes, they examine the freshly gathered eggs and prepare to inject a single rhesus sperm into each one. If all goes well, the team will introduce the genome editor CRISPR before the resulting embryo begins to grow—early enough for the mutation for aging to show up in all cells of any offspring.

Continue reading “China’s CRISPR push in animals promises better meat, novel therapies, and pig organs for people” »

Aug 7, 2019

Position Statement 56: Mental Health Treatment in Correctional Facilities

Posted by in categories: biotech/medical, health, law enforcement, neuroscience

“Over the past 50 years [America has] gone from institutionalizing people with mental illnesses, often in subhuman conditions, [in state mental health hospitals] to incarcerating them at unprecedented and appalling rates—putting recovery out of reach for millions of Americans […] On any given day, between 300,000 and 400,000 people with mental illnesses are incarcerated in jails and prisons across the United States, and more than 500,000 people with mental illnesses are under correctional control in the community.” [1] Mental Health America (MHA) supports effective, accessible mental health treatment for all people who need it who are confined in adult or juvenile correctional facilities or under correctional control. People with mental health and substance use conditions also need an effective classification system to protect vulnerable prisoners and preserve their human rights. [2] Notwithstanding their loss of their liberty, prisoners with mental health and substance use conditions retain all other rights, and these must be zealously defended.

Background

In the past decade, America has been locking up increasing numbers of individuals with mental health conditions. [3] MHA is both concerned by and opposed to the increasing use of criminal sanctions and incarceration, replacing the state mental hospitals with much more drastic curtailment of personal liberty and preclusion of community integration and community-based treatment. [4] Prisoners with mental health conditions are especially vulnerable to the difficult and sometimes deplorable conditions that prevail in jails, prisons, and other correctional facilities. Overcrowding often contributes to inadequacy of mental health services and to ineffective classification and separation of prisoner classes. It can both increase vulnerability and exacerbate mental illnesses. For these and other reasons, MHA supports maximum reasonable diversion. [5].

Aug 7, 2019

IBM just made its cancer-fighting AI projects open-source

Posted by in categories: biotech/medical, robotics/AI

IBM recently developed three artificial intelligence tools that could help medical researchers fight cancer.

Now, the company has decided to make all three tools open-source, meaning scientists will be able to use them in their research whenever they please, according to ZDNet. The tools are designed to streamline the cancer drug development process and help scientists stay on top of newly-published research — so, if they prove useful, it could mean more cancer treatments coming through the pipeline more rapidly than before.

Aug 7, 2019

Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing

Posted by in categories: biotech/medical, genetics

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene. The 3272–26AG and 3849+10kbCT CFTR mutations alter the correct splicing of the CFTR gene, generating new acceptor and donor splice sites respectively. Here we develop a genome editing approach to permanently correct these genetic defects, using a single crRNA and the Acidaminococcus sp. BV3L6, AsCas12a. This genetic repair strategy is highly precise, showing very strong discrimination between the wild-type and mutant sequence and a complete absence of detectable off-targets. The efficacy of this gene correction strategy is verified in intestinal organoids and airway epithelial cells derived from CF patients carrying the 3272–26AG or 3849+10kbCT mutations, showing efficient repair and complete functional recovery of the CFTR channel. These results demonstrate that allele-specific genome editing with AsCas12a can correct aberrant CFTR splicing mutations, paving the way for a permanent splicing correction in genetic diseases.

Aug 7, 2019

Heart Inflammation Causes a Shift in Cell Fate Distribution

Posted by in categories: biotech/medical, life extension

A study on animals with autoimmune myocarditis was recently released in the journal Cell Reports [1], showing the impact of heart inflammation on the types of immune cell that are formed in the heart. This could have a significant impact on our understanding of cardiac aging.

What is myocarditis and how is it relevant to aging?

Myocarditis is a disease involving inflammation of the heart. It mainly influences people between the ages of 20 and 51 [2] [3]; however, the elderly are still affected to some degree. The disease has been known to cause serious complications, such as heart attack and heart failure.

Aug 7, 2019

The intestinal microbiota fuelling metabolic inflammation

Posted by in category: biotech/medical

Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2 diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these disorders are characterized by alterations in the intestinal microbiota composition and its metabolites, which translocate from the gut across a disrupted intestinal barrier to affect various metabolic organs, such as the liver and adipose tissue, thereby contributing to metabolic inflammation. Here, we discuss some of the recently identified mechanisms that showcase the role of the intestinal microbiota and barrier dysfunction in metabolic inflammation. We propose a concept by which the gut microbiota fuels metabolic inflammation and dysregulation.